

## Table of Contents

Table of figures .....	iv
List of tables.....	v
ABBREVIATIONS.....	vi
1.0 INTRODUCTION.....	1
1.1 The human and simian immunodeficiency viruses.....	1
1.1.1 Origin and similarities, infection and pathogenesis.....	1
1.1.2 Gene structure and functions.....	2
1.1.3 Receptor-virus interactions.....	7
1.1.4 Replication, transcription and regulation of gene expression.....	9
1.1.5 Cytokines in immune response and regulation.....	10
1.1.6 Effects of chemokines on HIV/SIV infection.....	11
1.2 Pre-clinical models of HIV-1 vaccine studies.....	13
1.2.1 DNA Vaccines.....	14
1.2.2 Viral vector vaccines.....	15
1.3 Rationale for the study.....	16
1.4 Study Objectives.....	17
2.0 MATERIALS AND METHODS.....	19
2.1 General Methods.....	19
2.1.1 Immunogens.....	19
2.1.2 Experimental animals and design.....	21
2.1.3 Follow-up before and after challenge.....	22
2.1.4 Preparation of Peripheral Blood Mononuclear Cells.....	23
2.1.5 Preparation of virus stock for <i>in vitro</i> infections.....	23
2.1.6 Virus titration.....	23
2.1.7 Indirect Immunoperoxidase Assay.....	24
2.2 <i>Ex vivo</i> susceptibility assays.....	24
2.2.1 Infection of peripheral blood mononuclear cells.....	24
2.2.2 Preparation of DNA Plasmids for PCR standards.....	25
2.2.3 <i>In vitro</i> transcription and preparation of RNA standards for PCR.....	26
2.2.4 Isolation of viral RNA for quantitative PCR.....	28
2.2.5 Quantitative Real-time Reverse Transcriptase PCR.....	29
2.3 SIVgag-specific IFN $\gamma$ ELISPOT assays.....	30
2.4 CD-8+ T-cell non-cytotoxic antiviral response (CNAR) assay.....	31
2.5 Flow cytometry analyses.....	32
2.6 Macaque MHC-class 1 typing techniques.....	32
2.6.1 DNA preparation for MHC typing.....	32

2.6.2	MHC class I locus-specific PCR typing .....	33
2.7	Cytokine assays .....	34
2.7.2	Preparation of Standards for the assay .....	34
2.7.3	Cytokine bead array: principles of the assay .....	35
2.7.4	Cytokine bead array: assay procedures .....	35
2.8	Statistical analyses and determination of associations .....	37
3.0	RESULTS .....	38
3.1.1	Immunization significantly attenuates <i>ex vivo</i> susceptibility to SIV .....	38
3.2	Immune Correlates of <i>ex vivo</i> SIV suppression .....	43
3.2.1	Suppression of SIV <i>ex vivo</i> correlates with INF $\gamma$ -ELISPOT and CNAR .....	43
3.3	Progression to SIV infection after challenge .....	48
3.3.1	Immunisation leads to significant control of acute viremia after challenge .....	49
3.3.2	Immunization preserves memory CD4+ T-cells after challenge .....	53
3.4	Influence of MHC class-1 allele on susceptibility to SIV .....	54
3.4.1	PCR typing and MHC- class 1 <i>Mamu</i> allele frequencies .....	56
3.4.2	MHC- class 1 allele did not affect <i>ex vivo</i> susceptibility to SIV infection. ..	57
3.4.3	Influence of MHC class 1 on control of viremia after challenge .....	59
3.4.4	Expression of high frequency MHC-1 alleles is linked to rapid SIV replication and viremia turnover .....	61
3.5	Effect of chemokines and cytokines on <i>ex vivo</i> susceptibility to SIV .....	62
3.5.1	Secretion of $\beta$ -chemokines and cytokines is suppressed in <i>ex vivo</i> infected cells of immunised macaques. ....	63
3.5.2	Gama inducible protein 10 (IP10, or CXCL10) is lowered during effective viral control and increased during rapid virus replication .....	65
3.5.3	Association of chemokines and cytokines with SIV replication <i>ex vivo</i> ....	67
3.6.1	Pre-challenge VVR accurately predicts plasma viremia after challenge ...	70
3.6.2	Intrinsic susceptibility <i>ex vivo</i> predicts the number of memory CD4+ T-cells after challenge. ....	71
3.6.3	Pre-challenge CNAR but not IFN $\gamma$ ELISPOT correlate with plasma viremia and memory CD4+ T-cells counts .....	73
3.6.4	Pre-challenge secreted cytokine levels correlate with post-challenge plasma viremia and memory CD4+ T-cell counts .....	75
4.0	DISCUSSIONS .....	78
4.1	<i>Ex vivo</i> susceptibility to SIV infection .....	78
4.2	Control of viremia after challenge. ....	79
4.3	Influence of MHC-class 1 alleles on <i>ex vivo</i> and <i>in vivo</i> virus replication. ....	82
4.4	Influence of cytokines and chemokines on <i>ex vivo</i> SIV infection. ....	85
4.4.1	Kinetics of cytokines and chemokines in <i>ex vivo</i> infected PBMC cultures ....	85

4.4.2	Association of $\beta$ -chemokines and cytokines with <i>ex vivo</i> SIV replication.....	86
4.4.3	CXCL10 is associated with increased susceptibility to SIV. ....	88
4.5	<i>Ex vivo</i> model as a predictive surrogate for post-challenge outcome.....	89
4.5.1	Intrinsic susceptibility predicts viremia and CD4+ T-cell memory after challenge. ....	90
4.5.2	Pre-challenge CNAR but not IFN $\gamma$ ELISPOT predicts post-challenge plasma viremia and memory CD4+ T-cells. ....	90
4.5.3	Beta chemokines correlate differentially with efficacy of vaccine-induced protection. ....	92
4.5.4	Pre-challenge levels of CXCL10 correlate with post-challenge plasma viremia and memory CD4+ T-cells. ....	92
5.	CONCLUSIONS.....	94
6.0	SUMMARY.....	95
6.0	ZUSAMMENFASSUNG .....	97
7.0	REFERENCES.....	99
	APPENDIX.....	120
App. 1.1	REAGENTS AND MATERIALS USED FOR VARIOUS ASSAYS.....	120
	ACKNOWLEDGEMENT .....	129
	CURRICULUM VITAE AND BIBLIOGRAPHY.....	131
	LEBENS LAUF .....	132